Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Precolyst NT
- Development stage
- Unknown
- Lead developer
- Septalyst Lifesciences
- Administration
- Oral
01
Targets
KCNH2 (Voltage-gated potassium channel subfamily H member 2)HRH1 (Histamine H1 Receptor)mAChR (Muscarinic acetylcholine receptors)NET (Norepinephrine Transporter)SERT (Sodium-dependent serotonin transporter)ADRA1A (α1A)α2δ (Voltage-gated calcium channel alpha-2-delta subunit)
Beyond the preview
Go deeper on Precolyst NT.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Precolyst NT.